TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01046383

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IMN1207
Description: 20 grams of IMN1207 per day for 40 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Casein
Description: 20 grams of Casein per day for 40 weeks
Study: NCT01714297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalteparin 5000 IU s.c.
Description: All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalteparin 5000 IU s.c.
Description: All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
Study: NCT04875949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunoabsorption/plasmapheresis procedure
Study: NCT03733210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Air camera
Description: Fluorescence camera manufactured by SurgVision
Study: NCT00553631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: velaglucerase alfa
Description: IV infusion, 60 U/kg every other week for 9 months
Study: NCT00862121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentasa
Description: 6 g/day orally, 2 g in the morning and 4 g in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 g/day orally, 2 g in the morning and 4 g in the evening
Study: NCT01892397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune (NovoTTF-100A)
Study: NCT04209257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation.
Description: Functional electrical stimulation - electrical stimulation applied to a muscle during an activity (i.e. ankle dorsiflexors during swing phase of gait). It assists / elicits muscle activation in order to achieve a task.
Study: NCT00553631

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: imiglucerase
Description: IV infusion, 60 U/kg every other week for 9 months
Study: NCT00950651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl Contramid® Once A Day
Description: The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl Twice a day
Description: The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
Study: NCT01044030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol syrup
Description: 7.5 mL (5 grams) by mouth three times daily
Study: NCT02521688

Intervention type: PROCEDURE
Intervention: incisional biopsy from placenta and GCF sample
Description: A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
Study: NCT01044030

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.5 mL by mouth three times daily
Study: NCT02046018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICCM delivered by VHT
Description: VHT's deliver ICCM to children under five in their communities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICCM delivered by VHT
Description: VHT's deliver ICCM to children under five in their communities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICCM delivered by VHT with Cell Phone
Description: ICCM delivered to children under 5 by VHT trained in ICCM and given cell phones
Study: NCT03787732

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Bolus
Description: 500 milliliters of an intravenous crystalloid solution of the operator's choosing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Fluid Bolus
Description: No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation
Study: NCT00544518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benfluorex
Description: 2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
Study: NCT04561466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Béfizal
Description: 600 mf befizal a day for one year
Study: NCT02046018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: VHT's selected by no ICCM training given and no drugs or cell phones.
Study: NCT00800982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Narrow band (310-312 nm) ultraviolet light B phototherapy
Description: Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
Study: NCT04223258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Oxygen control
Description: The CLiO device is integral to the Avea infant ventilator and allows automated OXYGEN adjustment aiming to maintain SpO2 within assigned target range using neonatal pulse oximeter. When first started it adopts the FiO2 previously set by the clinician as the initial 'Baseline FiO2' level. Thereafter, the changes to the FiO2 and their frequency depend on whether SpO2 is below, above or within the target range, the trend in SpO2 and all changes are proportionate to the 'Baseline FiO2' level.
Study: NCT00894595

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Knäkontroll, SISU Idrottsböcker©, Sweden, 2005
Description: The preventive program (Knäkontroll, SISU Idrottsböcker©, Sweden, 2005) consists of six exercises focusing on knee control and core stability and is performed during the warm-up at two training sessions per week throughout the 2009 competitive season.
Study: NCT04218630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reformer pilates exercises
Description: The program consisted of 10 minutes warm-up exercises, reformer pilates exercises for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week and applied to be 12-15 repetitions in the last week. Increasing the resistance of the springs and adding different positions were used for progression of exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home mat pilates exercises
Description: The program consisted of 10 minutes warm-up exercises, clinical pilates-based exercises on mat for 40 minutes and 10 minutes cool-down exercises. The exercises were started with 6-8 repetitions, increased to 1-2 repetitions each week, and applied to be 12-15 repetitions in the last week.
Study: NCT03415334

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: behavioral development for change
Description: 1. Social Marketing Principles (4 Ps) Product, price, place and promotion~2. Communication for Behavior Development Approach 1. Interpersonal communication campaigns (IPC) 2. Mass media and public gathering awareness campaigns 3. Public health awareness campaigns 4. A village hotline and local satellite channel 5. School awareness raising events
Study: NCT04103658

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Near-infrared heating
Description: Same as the arm/group description. The NIR heating group will have the non-melanoma skin cancer lesion excised based on the lesion borders established from application of NIR heat at a distance of 20cm for 10 minutes.
Study: NCT03874637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treament
Description: Placement of the FemPulse System with therapy delivery

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Placement of the FemPulse System without therapy delivery
Study: NCT02787096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LaxIRM
Description: Dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
Study: NCT01399814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perioperative fluid management
Description: No preloading of epidural analgesia,7ml/kg lactated ringer's solution was administered in first hour,and 5ml/kg.h during the following hours,and 1000ml of glucose 5% was administered on the rest of the day during operation.1000\~1500ml crystalloid was administered on the days following operation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: perioperative fluid treatment
Description: 500 mL HAES 6% was accepted as preloading of epidural analgesia,12ml/kg.h lactated ringer's solution was administered during the operation ,and 1000ml of glucose 5% was administered on the rest of the day during operation.2000\~2500ml crystalloid was administered on the days following operation
Study: NCT04329403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% Gel
Description: A thin film of the assigned medication to be applied once daily in the evening for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin 0.1% Topical Gel
Description: A thin film of the assigned medication to be applied once daily in the evening for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A thin film of the assigned medication to be applied once daily in the evening for 12 weeks
Study: NCT02908360

Intervention type: GENETIC
Intervention: double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse

Intervention type: GENETIC
Intervention: double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse

Intervention type: GENETIC
Intervention: double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse
Study: NCT03273114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Functional Therapy
Description: There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~1. The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~2. Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~3. Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~4. Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies
Study: NCT02521688

Intervention type: PROCEDURE
Intervention: incisional biopsy from placenta and GCF sample
Description: A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.

Intervention type: PROCEDURE
Intervention: incisional biopsy from placenta and GCF sample
Description: A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
Study: NCT03273114

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Training Exercise and Manual Therapy
Description: According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with active exercises will involve contractions of abdominal and back muscles in different functional positions, as well as joint mobilization or manipulation techniques applied to the lower back or pélvis, when necessary. Most patients in this group will receive exercises to perform at home, but not related to CFT.
Study: NCT01430572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.
Study: NCT03675477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302
Description: The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a Janus kinase inhibitor).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Tablet
Study: NCT00249756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-entry Modified Therapeutic Community (Re-entry MTC)
Description: In general, the MTC program model applies three fundamental adjustments - increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parole Supervision and Case Management
Description: Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
Study: NCT01540838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusion with paracetamol
Description: The administration of 250 mg/kg/24 hours cefotaxime during the first 4 days as continuous intravenous infusion, each single infusion lasting for 12 hours (to prevent degradation of the agent), combined with high-dose paracetamol orally; the first dose is 30 mg/kg, then 20 mg/kg every 6 hours for 4 full days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bolus without paracetamol
Description: The control intervention consists of 250 mg/kg/24 hours cefotaxime administered traditionally with intermittent i.v. boluses and the place bo of paracetamol orally, both repeated every 6 hours (qid) for 4 days.
Study: NCT02981264

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transcricoid Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spray as you go
Study: NCT00493025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Gefitinib IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Postoperative ZD1839
Study: NCT04223258

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Oxygen Control
Description: In the manual arm the oxygen is adjusted manually by the clinical team.
Study: NCT00493025

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiotherapy
Study: NCT03068455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified Dose on Specified Days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Specified Dose on Specified Days
Study: NCT02192138

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic thoracentesis
Description: Therapeutic thoracentesis with pleural fluid withdrawal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleural catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleural manometer
Study: NCT04454294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Common Process Steps:~1. Informed consent forms will be signed by those who wish to take part in the research.~2. The form in which individual characteristics are questioned will be filled.~3. Hands will be washed, gloves will be worn.~4. Before the procedure, body temperature, heart rate, respiratory rate, blood pressure, oxygen saturation and bleeding amount will be recorded.~5. Drains will be kept parallel to the ground and upright.~6. Drainage hoses will not be bent and in-bed position will be provided in accordance with gravity.~7. It will be ensured that all connections between the chest tubes and drainage unit are tight and secure.~8. Dressings of the chest and mediastinum drains will be fixed on the patient's skin, so as not to interfere with drainage.~9. To prevent the tubes from coming out, they will be fixed to the patient bed.~Vital signs, Sp02 and bleeding amount will be recorded every hour for 6 hours after surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group (Absorption Group)
Description: 1. Common process steps~2. Appropriate negative pressure monitoring system of the patient, who is admitted to the intensive care unit with underwater drainage system, will be established.~   * The suction control room combined with the vacuum regulator will be filled with sterile distilled water up to the specified level (20 cm H2O).~  * From the vacuum regulator, the drain or drains will be connected tightly and by preventing the crimping, from the aspirator receptor hoses.~3. Suction will begin with a low level and gradually increase the suction until a slight bubble is noticed in the suction control room.~4. Suction pressure will be maintained between 5 and 15 kPa (kilopascals) or 10-20 cm H20.~5. The application will continue without interruption until the patient's drain need and the doctor's request is ended.~6. During the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group (Milking Group)
Description: 1. Common process steps will be applied~2. Operation will start from the area near the drain entrance point~3. Latex tube will be folded into 12 cm long pieces and will be gripped with two hands~4. The procedure will be repeated 3 times by compressing the parts gripped by the nurse hand.~5. This process will be repeated in the distal part.~6. After the application, the patient's vital signs, Sp02 and bleeding amount will be recorded every hour without using an additional manipulation method.
Study: NCT03706079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study: NCT00752453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis during 4 hours
Description: Blood and dialysate sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis during 6 hours
Description: Blood and dialysate sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis during 8 hours
Description: Blood and dialysate sampling
Study: NCT01003834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized brief intervention
Description: Intervention based on Motivational Interviewing technique